In-vitro induction method of pancreatic beta cells

Through the three-step induction culture scheme and the optimization of specific culture medium components, the induction rate and quality of pancreatic β cells are improved, the problem of insufficient induction rate and quality in the prior art is solved, and efficient islet β cell generation and proliferation are achieved. .

CN118909926APending Publication Date: 2024-11-08SHAANXI BEITIAN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411166197.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The induction rate and product cell quality of islet β-cell induction schemes in the prior art need to be improved, and it is difficult to meet the needs of a large number of diabetic patients.

Method used

Using a three-step induction culture scheme, human umbilical cord mesenchymal stem cells were induced in the initial, mid- and late induction medium, including 2-mercaptoethanol aqueous solution, exenatide, β-nerve growth factor, ActivinA, and epidermal growth Components such as factor and B27 supplements, optimize induction conditions to improve the induction rate and quality of pancreatic β cells.

Benefits of technology

It significantly improves the induction rate of pancreatic β cells and the quality of product cells, promotes the proliferation and survival of cells, and improves the sensitivity to sugar stimulation and insulin secretion ability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909926A_ABST
    Figure CN118909926A_ABST
Patent Text Reader

Abstract

The invention provides an in-vitro induction method of pancreatic beta cells, and belongs to the technical field of cell culture. By adopting a specific three-step induction scheme, the problem that the induction rate and the product cell quality of an islet beta cell induction scheme in the prior art need to be further improved can be solved. According to the scheme provided by the invention, the pancreatic beta cells can be successfully induced by using the human umbilical cord mesenchymal stem cells, the proliferation and survival conditions of the obtained pancreatic beta cells can be promoted, and the product cell quality is further optimized while the induction rate is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of cell culture, and in particular to an in vitro induction method for pancreatic beta cells. Background Art

[0002] Diabetes is one of the major diseases that affect human health. Insufficient insulin secretion and disordered glucose metabolism caused by decreased pancreatic β-cell function are important causes of diabetes. While studying the pathogenesis, studying the functional status of pancreatic cells is an important part. Currently, many experiments have shown that pancreatic β-cell replacement therapy - pancreatic β-cell transplantation is an effective way to cure diabetes. However, due to the huge number of diabetic patients, the problem of cell source remains to be solved. Stem cells, as a type of cell with multidirectional differentiation potential, can become an ideal resource for pancreatic β-cell replacement.

[0003] Chinese patent CN113583938A discloses a method for inducing islet cells differentiated from stem cells to form islet-like structures in vitro, comprising the following steps: isolating and culturing raw tissue to obtain mesenchymal stem cells; subculturing the obtained mesenchymal stem cells; inducing differentiation of the obtained subcultured mesenchymal stem cells into islet-like cells. The invention adopts a specific induction culture medium (containing beta-cell factor, EGF, niacinamide, and human basic fibroblast growth factor) and pretreatment and induction culture steps, which can quickly and efficiently induce islet cells differentiated from stem cells in vitro to form islet-like structures.

[0004] However, the induction rate and product cell quality of the pancreatic β cell induction scheme in the existing technology need to be further improved. Summary of the invention

[0005] The purpose of the present invention is to provide an in vitro induction method for pancreatic β cells, which can improve the induction rate of pancreatic β cells and the quality of product cells.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides an in vitro induction method for pancreatic β cells, comprising the following steps:

[0008] S1. Inoculate human umbilical cord mesenchymal stem cells into the initial induction medium for the first stage of induction culture;

[0009] S2, transferring the cells obtained in S1 into the mid-stage induction medium for the second stage of induction culture;

[0010] S3, transferring the cells obtained in S2 into the late induction medium, and performing the third stage induction culture to obtain pancreatic β cells;

[0011] The initial induction medium contains a 2-mercaptoethanol aqueous solution.

[0012] Preferably, in the initial induction medium, the volume percentage concentration of the 2-mercaptoethanol aqueous solution is 0.5-2%.

[0013] Preferably, the initial volume percentage concentration of the 2-mercaptoethanol aqueous solution is 0.02% to 0.04%.

[0014] Preferably, the late induction medium contains exenatide.

[0015] Preferably, in the late induction medium, the final concentration of exenatide is 30-80 nmol / L.

[0016] Preferably, the late induction medium further comprises the following components at final concentrations:

[0017] 10-20mmol / L niacinamide, 5-15μg / L bFGF and 5-7% growth factor.

[0018] Preferably, the mid-term induction medium contains the following components at final concentrations:

[0019] 80-120μg / Lβ-nerve growth factor, 3-5nmol / L ActivinA, 20-30μg / L epidermal growth factor, 1-3% B27 supplement and 5-7% growth factor.

[0020] Preferably, the first stage of induction culture lasts for 1 to 4 days;

[0021] The second stage of induction culture lasts for 5 to 10 days;

[0022] The duration of the third stage induction culture is 5 to 10 days.

[0023] Preferably, in S1, the seeding density of the human umbilical cord mesenchymal stem cells is 5×10 4 ~5×10 5 Pieces / hole;

[0024] And / or, the human umbilical cord mesenchymal stem cells are human umbilical cord mesenchymal stem cells of the third generation of subculture.

[0025] Preferably, the initial induction medium uses a serum-free medium as a basal medium;

[0026] The mid-term induction medium uses a serum-free medium as a basic medium;

[0027] The late induction medium uses a serum-free medium as a basic medium.

[0028] Beneficial effects of the present invention:

[0029] The present invention adopts a specific three-step induction scheme, which can successfully induce pancreatic beta cells using human umbilical cord mesenchymal stem cells, and promote the proliferation and survival of the obtained pancreatic beta cells, thereby further optimizing the product cell quality while improving the induction rate. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 These are photos of cells taken under an inverted microscope for 3-4 days (×40);

[0031] Figure 2 Figure 1 is the result of flow cytometry analysis;

[0032] Figure 3 Light microscopic photograph of cells in the experimental group induced for differentiation for 12 days (×400);

[0033] Figure 4 This is a light microscopic photograph of cells in the control group after 12 days of induction of differentiation (×400);

[0034] Figure 5 This is the result of dithizone staining of the cell clusters in the experimental group after induction;

[0035] Figure 6 This is the result of dithizone staining of cells in the uninduced control group;

[0036] Figure 7 The results of PDX-1 and Insulin expression at P2, P4, and P6 after induction are shown in the figure, where the left column shows the results of the control group and the right column shows the results of the experimental group;

[0037] Figure 8 Glucose stimulated insulin secretion in cells of control group 1, control group 2 and experimental group;

[0038] Fig. 9 Cell apoptosis and necrosis in control group 1, control group 2 and experimental group. DETAILED DESCRIPTION

[0039] The present invention provides an in vitro induction method for pancreatic β cells, comprising the following steps:

[0040] S1. Inoculate human umbilical cord mesenchymal stem cells into the initial induction medium for the first stage of induction culture;

[0041] S2, transferring the cells obtained in S1 into the mid-stage induction medium for the second stage of induction culture;

[0042] S3. The cells obtained in S2 are transferred into the late induction culture medium for the third stage of induction culture to obtain pancreatic β cells.

[0043] In the present invention, in S1, the seeding density of the human umbilical cord mesenchymal stem cells is preferably 5×104 ~5×10 5 / well; the human umbilical cord mesenchymal stem cells are preferably human umbilical cord mesenchymal stem cells of the third generation of subculture; the initial induction medium preferably uses a serum-free medium as a basic medium; the initial induction medium contains a 2-mercaptoethanol aqueous solution, and the volume percentage concentration of the 2-mercaptoethanol aqueous solution in the initial induction medium is preferably 0.5-2%, and more preferably 1%; the initial volume percentage concentration of the 2-mercaptoethanol aqueous solution is preferably 0.02%-0.04%, and more preferably 0.035%; the time for the first stage of induction culture is preferably 1 to 4 days.

[0044] In the present invention, the mid-stage induction medium preferably contains the following components at final concentrations: 80-120 μg / L β-nerve growth factor, 3-5 nmol / L ActivinA, 20-30 μg / L epidermal growth factor, 1-3% B27 supplement and 5-7% growth factor; the mid-stage induction medium preferably uses serum-free medium as the basal medium; the time for the second stage induction culture is preferably 5-10 days.

[0045] In the present invention, the late induction medium preferably contains exenatide; in the late induction medium, the final concentration of exenatide is preferably 30-80 nmol / L; the late induction medium also preferably contains the following components at final concentrations: 10-20 mmol / L niacinamide, 5-15 μg / L bFGF and 5-7% growth factor; the late induction medium preferably uses serum-free medium as the basal medium; the time of the third stage induction culture is preferably 5-10 days.

[0046] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0047] The sources and specific information of the reagents used in the examples are as follows:

[0048] Basic fibroblast growth factor, item number: 100-18B-50, brand: peprotech;

[0049] Serum-free culture medium, catalog number: SC2013-G, brand: Tianjin Haoyang;

[0050] β-nerve growth factor, product number: 450-01-100, brand: peprotech;

[0051] Epidermal growth factor, item number: AF-100-15-100, brand: peprotech.

[0052] The human umbilical cord mesenchymal stem cell isolation and subculture method used in the embodiment is as follows:

[0053] Under sterile conditions, take the umbilical cord of a healthy fetus delivered by cesarean section at full term, about 20 cm long, rinse it thoroughly with 0.01mmol / L PBS buffer, and process it within 4-6 hours after the umbilical cord is removed from the body. Remove the artery and vein of the umbilical cord in the clean bench, peel off the Wharton's jelly, and cut it into 1.0-2.0mm pieces. 3 The tissue blocks were attached to the bottom of the culture flask, and serum-free culture medium containing 6% growth factor by volume was added and cultured in a 37°C incubator.

[0054] After 2 weeks of culture, the tissue block was removed and subcultured when the adherent cells reached 80%-90%, and digested with 2.5g / L trypsin. During the digestion process, the cell digestion was observed under an inverted microscope. When most of the cell bodies shrank and became round, the digestion was terminated, and then divided into 2-3 parts for subculture, recorded as P1 generation. The medium was replaced every 3 days of subculture. After the adherent cells merged and covered the bottom of the bottle, the above operation was repeated, and the culture was continued as P2 generation.

[0055] Take the third generation cells, wait for them to grow to 80%-90%, digest them with 2.5g / L trypsin, centrifuge the cells and wash them twice with PBS, finally add 1mL PBS to resuspend the cells, count them, and add 2.5×10 6 cells / mL for flow cytometry analysis.

[0056] Example

[0057] Preparation of induction solution: Dissolve 7 μL of 2-mercaptoethanol in 20 mL of water (tissue culture grade) to make a 100× storage solution, aseptically dispense into 1 mL EP tubes through microporous filtration to obtain the induction solution - 2-mercaptoethanol storage solution. Dilute with serum-free culture medium before use, add 1 mL of 2-mercaptoethanol storage solution to every 99 mL of serum-free culture medium, and mix to obtain the induction solution.

[0058] The third generation human umbilical cord mesenchymal stem cells were seeded in a 6-well plate at a cell seeding density of 2×10 5 The experimental group was induced with the above-mentioned induction solution, and the control group was simply cultured with DMEM / F12 medium. The induction was carried out using a three-step method:

[0059] S1, initial induction (0-2 days), add 2.5 mL of the above-prepared induction solution to each well;

[0060] S2, mid-stage induction (2-9 days), discard the supernatant and replace the culture medium with a serum-free medium containing 100 μg / L β-nerve growth factor, 4 nmol / L Activin A, 25 μg / L epidermal growth factor, 2% B27 supplement, and 6% growth factor;

[0061] S3, late induction (9-16 days), discard the supernatant, replace the culture medium with a serum-free culture medium containing 20mmol / L niacinamide, 10μg / L basic fibroblast growth factor (bFGF), 50nmol / L exenatide, and 6% growth factor to induce pancreatic β cells.

[0062] During the above-mentioned induction culture process, the culture conditions are: culture temperature: 35-39°C, CO2 concentration: 3-8%.

[0063] Experimental Example 1

[0064] Morphological observation of human umbilical cord mesenchymal stem cells:

[0065] After the umbilical cord was separated and digested with trypsin, the single cells were counted with trypan blue and >96%. In the culture medium, the cells began to adhere to the wall 4 hours after inoculation, and the cells were completely attached to the wall after 2 days. After 3-4 days, the cells showed a long spindle shape like fibroblasts under an inverted microscope, grew evenly, and were arranged roughly in parallel, showing a fibroblast-like cell morphology, such as Figure 1 shown.

[0066] Flow cytometric analysis results of human umbilical cord mesenchymal stem cells

[0067] HUMSCs adherent to the wall at P3 were cultured and the following mouse anti-human monoclonal antibodies labeled with FITC were added: CD90, CD105, CD34, CD45, and the expression of cell surface markers was detected by flow cytometry. The results of flow cytometric analysis showed that cells isolated and cultured from the umbilical cord highly expressed CD90 and CD105, and very low expression of CD45 and CD34. As shown in Table 1 and Figure 2 shown.

[0068] Table 1 Flow cytometry analysis results

[0069] project result(%) CD90+ 99.65 CD105+ 99.18 CD34+ 0.26 CD45+ 0.35

[0070] Identification of induced islet-like cell clusters:

[0071] Morphological observation: Observe and take pictures under an inverted phase contrast microscope 9 and 16 days after induction;

[0072] Dithizone staining: 1 mg of dithizone was completely dissolved in 10 mL of triple distilled water to prepare a 10% dithizone solution. The old culture medium was discarded, and after rinsing with PBS, 50.0 μL of dithizone solution was added to 30 mL of sterile PBS. Mix well, and 3 mL of the mixture was added to each well. After 10 min at room temperature, the cells were observed and photographed under an inverted microscope.

[0073] RNA extraction and RT-PCR analysis: P2, P4, and P6 HUMSCs were induced and the total RNA of the experimental and control groups was extracted with reference to Trizol (Invitrogen, USA). 1 μg RNA was synthesized into cDNA. The method of PCR identification of human insulin and PDX-1 expression was performed according to the instructions of RNA PCR kit (Beijing Tiangen Biochemical Technology Co., Ltd.). Gene primers were designed using primer 5 software and synthesized by Invitrogen. The primer sequence table is shown in Table 2.

[0074] Table 2 PCR primers and parameters

[0075]

[0076] Identification results of islet-like cell clusters

[0077] The morphological observation results are shown in Figures 3-4 After 9 days of induction and differentiation, the morphology began to change from the original fibrous shape to round, polygonal and irregular shapes. Some cells gradually turned into cell clusters, and local cells began to gather. After about half a month of culture, a spherical pancreatic islet-like cell cluster structure was formed, which was connected to the bottom of the bottle with a slender pedicle and floated in the culture medium. Figure 3 ). The control group showed little change ( Figure 4 ).

[0078] The results of dithizone staining are as follows Figures 5-6 As shown: The cytoplasm of some cells in the experimental group was stained brown-red, showing dithizone positive staining ( Figure 5 ), while the control group was not stained ( Figure 6 ).

[0079] The expression of PDX-1 and Insulin after HUMSCs induction Figure 7 As shown: PDX-1 was detected in the experimental group cells while PDX-1 was not expressed in the control group; after 6 days of induction, the insulin gene Insulin was positively expressed in the experimental group while Insulin was not expressed in the control group.

[0080] Experimental Example 2

[0081] Control group setting:

[0082] The third generation human umbilical cord mesenchymal stem cells were seeded in a 6-well plate at a cell seeding density of 2×10 5 / well, the experimental group was cultured with induction solution. The control group 1 was cultured with DMEM / F12 medium alone. The control group 2 was cultured without adding 50nmol / L exenatide during the late induction of the culture system.

[0083] ELISA to detect insulin secretion after glucose stimulation of induced cells

[0084] The results of Insulin-ELISA kit showed that the cells in control group 1, control group 2 and experimental group were stimulated with low glucose (containing 5.6 mmol / L glucose) for 2 h, and 1×10 5 The secretion of Insulin per cell / ml was (1.70±0.29)pg, (73.74±10.03)pg, (166.37±18.54)pg, respectively. After stimulation with high-glucose (containing 23.3mmol / L glucose) medium for 2h, the secretion of Insulin was (1.70±0.33)pg, (84.03±14.64)pg, (392.78±28.82)pg, respectively. Figure 8 As shown in the figure, the control group 1 secreted almost no insulin; the control group 2 and the experimental group both secreted insulin, and as the sugar concentration increased, the secretion of the experimental group also increased significantly, increasing by nearly 1.5 times, indicating that the experimental group was sensitive to sugar stimulation, and its insulin secretion was significantly regulated by the external environment sugar.

[0085] AnnexinV-EGFP apoptosis detection kit was used to detect cell apoptosis after induction under direct flow cytometry (FACS)

[0086] Under FCM, fluorescence compensation was adjusted by negative control and positive control, and a cross gate was set to divide the cells into four areas. The cells in area Q3 were normal cells, area Q4 were apoptotic cells, area Q2 were necrotic cells, and area Q1 were dead cells mechanically damaged during the experimental operation. The percentages of apoptotic cells and necrotic cells in the control group 1, control group 2, and experimental group were detected. The results are shown in the figure. Fig. 9 And as shown in Table 3.

[0087] Table 3 Percentage of apoptotic and necrotic cells in control group 1, control group 2 and experimental group

[0088] variable Q4 (apoptosis)% Q2 (necrosis)% Control group 1 7.70±0.76 0.80±0.10 Control group 2 11.73±2.32 2.10±0.17 Experimental Group 9.06±0.14 1.00±0.10

[0089] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. An in vitro method for inducing pancreatic β cells, characterized in that: The following steps are involved: S1. Inoculate human umbilical cord mesenchymal stem cells into the initial induction medium for the first stage of induction culture; S2, transferring the cells obtained in S1 into the mid-stage induction medium for the second stage of induction culture; S3, transferring the cells obtained in S2 into the late induction medium, and performing the third stage induction culture to obtain pancreatic β cells; The initial induction medium contains a 2-mercaptoethanol aqueous solution.

2. The in vitro induction method of pancreatic β cells according to claim 1, characterized in that: In the initial induction culture medium, the volume percentage concentration of the 2-mercaptoethanol aqueous solution is 0.5-2%.

3. The in vitro induction method of pancreatic β cells according to claim 2, characterized in that: The initial volume percentage concentration of the 2-mercaptoethanol aqueous solution is 0.02% to 0.04%.

4. The in vitro induction method of pancreatic β cells according to claim 1, characterized in that: The late induction culture medium contains Exenatide.

5. The in vitro induction method of pancreatic β cells according to claim 4, characterized in that: In the late induction culture medium, the final concentration of exenatide is 30-80 nmol / L.

6. The in vitro induction method of pancreatic β cells according to claim 4, characterized in that: The late induction medium further comprises the following components at final concentrations: 10-20mmol / L niacinamide, 5-15μg / L bFGF and 5-7% growth factor.

7. The in vitro induction method of pancreatic β cells according to claim 1, characterized in that: The mid-term induction medium contains the following components at final concentrations: 80-120μg / Lβ-nerve growth factor, 3-5nmol / L ActivinA, 20-30μg / L epidermal growth factor, 1-3% B27 supplement and 5-7% growth factor.

8. The in vitro induction method of pancreatic β cells according to claim 1, characterized in that: The first stage of induction culture lasts for 1 to 4 days; The second stage of induction culture lasts for 5 to 10 days; The duration of the third stage induction culture is 5 to 10 days.

9. The in vitro induction method of pancreatic β cells according to claim 1, characterized in that: In S1, the seeding density of the human umbilical cord mesenchymal stem cells is 5×10 4 ~5×10 5 Pieces / hole; And / or, the human umbilical cord mesenchymal stem cells are human umbilical cord mesenchymal stem cells of the third generation of subculture.

10. The in vitro induction method of pancreatic β cells according to any one of claims 1 to 9, characterized in that: The initial induction medium uses a serum-free medium as a basic medium; The mid-term induction medium uses a serum-free medium as a basic medium; The late induction medium uses a serum-free medium as a basic medium.